Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 3/20 | 0.58 |
| ▸ | JAK2 | O60674 | 3/20 | 0.58 |
| ▸ | FLT3 | P36888 | 3/20 | 0.51 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.51 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.51 |
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.51 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.51 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.51 |
| ▸ | CSF1R | P07333 | 2/20 | 0.51 |
| ▸ | CLK2 | P49760 | 2/20 | 0.51 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.51 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.51 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.51 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.51 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.51 |
| ▸ | FER | P16591 | 1/20 | 0.51 |
| ▸ | CDK2 | P24941 | 1/20 | 0.51 |
| ▸ | MARK3 | P27448 | 1/20 | 0.51 |
| ▸ | FLT4 | P35916 | 1/20 | 0.51 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1144803 | 0.86 | PDPK1 (0.54) | PDPK1JAK2FLT3CLK4DYRK1A | |
| SCHEMBL11388 | 0.86 | PDPK1 (0.58) | PDPK1JAK2FLT3CLK4DYRK1A | |
| SCHEMBL22632566 | 0.82 | PDPK1 (0.50) | PDPK1JAK2FLT3CLK4DYRK1A | |
| SCHEMBL1271820 | 0.82 | PDPK1 (0.58) | PDPK1JAK2FLT3CLK4DYRK1A | |
| SCHEMBL14338765 | 0.82 | PDPK1 (0.58) | PDPK1JAK2FLT3CLK4DYRK1A | |
| SCHEMBL7486071 | 0.81 | JAK2 (0.53) | PDPK1JAK2FLT3CLK4DYRK1A | |
| SCHEMBL7352631 | 0.80 | MAP2K4 (0.50) | FADS1MAPTCHEK1HPGD | |
| SCHEMBL7978106 | 0.80 | HTR1D (0.41) | GSK3BMEN1MAPTKMT2AFGFR1 | |
| SCHEMBL18555706 | 0.79 | PDPK1 (0.50) | PDPK1JAK2FLT3CLK4DYRK1A | |
| SCHEMBL905990 | 0.79 | PDPK1 (0.54) | PDPK1JAK2FLT3CLK4DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12528791-B2 | Thyroid hormone receptor beta agonist compounds | TERNS PHARMACEUTICALS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-12479836-B2 | Sphingosine-1-phosphate receptor agonist, preparation method therefor, and pharmaceutical composition containing same as active ingredient | LG CHEM, LTD. (KR) | 2025-11-25 | — | — | US | disclosed |
| CN-117247392-A | Carbazolophenazinyl-containing compound, intermediate for preparing carbazolophenazinyl-containing compound and application of carbazolophenazinyl-containing compound | 阜阳欣奕华材料科技有限公司 | 2023-12-19 | — | — | CN | disclosed |
| EP-4050010-B1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONIST, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE AGENT | LG CHEMICAL LTD (KR) | 2023-10-18 | — | — | EP | disclosed |
| US-11731953-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11731953-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11731953-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| EP-4168411-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | PMV Pharmaceuticals, Inc. (US) | 2023-04-26 | — | — | EP | disclosed |
| US-20230056253-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2023-02-23 | — | — | US | disclosed |
| US-20230056253-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2023-02-23 | — | — | US | disclosed |
| US-20080194661-A1 | Antifungal Triazole Derivatives | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2008-08-14 | — | — | US | disclosed |
| CN-101146796-A | 3-(indazol-5-yl)-(1,2,4)triazine derivatives and related compounds as protein kinase inhibitors for the treatment of cancer | SCHERING CORP (US) | 2008-03-19 | — | — | CN | disclosed |
| US-20080004257-A1 | Kinase inhibitors | SCHERING CORPORATION | 2008-01-03 | — | — | US | disclosed |
| US-20080004257-A1 | Kinase inhibitors | SCHERING CORPORATION | 2008-01-03 | — | — | US | disclosed |
| US-20080004257-A1 | Kinase inhibitors | SCHERING CORPORATION | 2008-01-03 | — | — | US | disclosed |
| EP-1871765-A2 | 3-(INDAZOL-5-YL)-(1,2,4)TRIAZINE DERIVATIVES AND RELATED COMPOUNDS AS PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF CANCER | SCHERING CORPORATION (US) | 2008-01-02 | — | — | EP | disclosed |
| US-20070185152-A1 | Inhibitors of akt activity | SMITHKLINE BEECHAM CORPORATION | 2007-08-09 | — | — | US | disclosed |
| US-20070185152-A1 | Inhibitors of akt activity | SMITHKLINE BEECHAM CORPORATION | 2007-08-09 | — | — | US | disclosed |
| US-20070185152-A1 | Inhibitors of akt activity | SMITHKLINE BEECHAM CORPORATION | 2007-08-09 | — | — | US | disclosed |
| WO-2006081230-A2 | 3-(INDAZOL-5-YL)-(1,2, 4) TRIAZINE DERIVATIVES AND RELATED COMPOUNDS AS PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF CANCER | SCHERING CORPORATION (US) | 2006-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12479836-B2 | Sphingosine-1-phosphate receptor agonist, preparation method therefor, and pharmaceutical composition containing same as active ingredient | S1PR1, S1PR2, S1PR4 | PDPK1 283/4885JAK2 2846/4885FLT3 1860/4885 |
| US-20070185152-A1 | Inhibitors of akt activity | AKT1, AKT1S1, AKT2 | PDPK1 8/4885JAK2 145/4885FLT3 1187/4885 |
| US-20230056253-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, HRAS | PDPK1 1391/4885JAK2 3815/4885FLT3 2568/4885 |
| US-11731953-B2 | Methods and compounds for restoring mutant p53 function | TP53, TP53BP1, HRAS | PDPK1 1391/4885JAK2 3815/4885FLT3 2568/4885 |
| US-12528791-B2 | Thyroid hormone receptor beta agonist compounds | THRB, THRA, TSHR | PDPK1 3534/4885JAK2 897/4885FLT3 1845/4885 |
| US-20080004257-A1 | Kinase inhibitors | MAP3K1, MAP3K13, MAP3K6 | PDPK1 55/4885JAK2 76/4885FLT3 439/4885 |
| US-20080194661-A1 | Antifungal Triazole Derivatives | ERG28, CYP51A1, CYP3A43 | PDPK1 1118/4885JAK2 1602/4885FLT3 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.